Review Article
Glycolysis in the African Trypanosome: Targeting Enzymes and Their Subcellular Compartments for Therapeutic Development
Table 1
The T. brucei glycolytic enzymes as potential drug targets.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
aFor enzyme abbreviations, see Figure 1. CAMTA1: calmodulin binding transcription activator 1; HKDC1: hexokinase domain containing protein 1; HXK3: hexokinase type 3; N/A: not applicable because the protein is cytosolic; PKLR: pyruvate kinase, liver, and RBC. bStatus: CV: chemically validated target—inhibitors against the target are toxic to parasites; GV: genetically validated target—genetic manipulation of the enzyme leads to growth defects or cell death. |